Analysis of key targets of brigatinib/brigatinib

Brigatinib (Brigatinib) is an innovative drug that has shown excellent therapeutic effects in non-small cell lung cancer and those cases that are resistant to traditional ALK inhibitors. Its powerful anti-cancer ability is mainly due to its unique chemical structure, which combines multiple functional groups and phosphorus elements that can tightly bind to target proteins.

The anti-cancer mechanism of brigatinib is mainly through inhibiting the activity of kinases such as ALK (anaplastic lymphoma kinase), insulin growth factor receptor-1, EGFR (epidermal growth factor receptor) and CD135 (or FLT3, fms-like tyrosine kinase 3). It specifically blocks the connection between the phosphate group and ALK, thereby stopping the phosphorylation process of other proteins related to lung cancer. In addition, according to multiple studies on mice, brigatinib can also effectively inhibit the growth of various cell lines and prevent the production of nucleophosmin and ALK fusion genes. Even mutants such as G1202R and L1196M are among its inhibitors.

It is worth mentioning that the effectiveness of brigatinib is not limited to the treatment of lung cancer. In fact, when the drug concentration is lower than 500nM, it has shown a significant inhibitory effect on the carcinogenic ability of cells, bringing new treatment options to patients with brain diseases. However, although brigatinib is considered a relatively safe drug, some patients on standard doses have reported common side effects such as increased blood sugar, nausea, diarrhea, cough and headache. In addition, a small number of patients may experience less common adverse reactions such as hypertension, pneumonia, interstitial lung disease/pneumonitis, and visual impairment.